title: Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.
abstract: Over the past several decades, the evidence supporting rational pediatric asthma management has grown considerably. As more is learned about the various phenotypes of asthma, the complexity of management will continue to grow. This article focuses on the evidence supporting the current guidelines-based pediatric asthma management and explores the future of asthma management with respect to phenotypic heterogeneity and biologics.
authors.affiliation: Division of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
authors.forename: Michelle Fox
authors.initials: MF
authors.lastname: Huffaker
authors.affiliation: Division of Immunology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA. Electronic address: wanda.phipatanakul@childrens.harvard.edu.
authors.forename: Wanda
authors.initials: W
authors.lastname: Phipatanakul
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001688:Biological Products / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D055118:Medication Adherence; D009330:Nebulizers and Vaporizers; D000069444:Omalizumab; D011788:Quality of Life
chemical_list: D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D000069444:Omalizumab
keywords: Asthma; Asthma management; Biologics; Omalizumab; Pediatric asthma